Computer model of the interaction of human TFPI-2 Kunitz-type serine protease inhibitor with human plasmin [3]

Thrombosis Research

Volumn 111, Issue 3, 2003, Pages 197-198

  Hube F ^a   Reverdiau, P ^a   Iochmann, S ^a   Gruel, Y ^a  

^a UNIVERSITÉ DE TOURS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; APROTININ; ARGININE; CARBON; GLUTAMINE; HYDROGEN; PLACENTA PROTEIN 5; PLASMIN; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; TRYPSIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AQUEOUS SOLUTION; ATOMIC PARTICLE; COMPUTER MODEL; ELECTRICITY; ENERGY; HUMAN; HYDROGEN BOND; IONIC STRENGTH; LETTER; MOLECULAR RECOGNITION; PH; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; SITE DIRECTED MUTAGENESIS; STEREOCHEMISTRY;

EID: 0346219300     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2003.09.021     Document Type: Letter

References (10)

1. Petersen L.C., Sprecher C.A., Foster D.C., Blumberg H., Hamamoto T., Kisiel W. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor. Biochemistry. 35:1996;266-272.
2. Rao C.N., Mohanam S., Puppala A., Rao J.S. Regulation of ProMMP-1 and ProMMP-3 activation by tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor. Biochem. Biophys. Res. Commun. 255:1999;94-98.
3. Konduri S.D., Rao C.N., Chandrasekar N., Tasiou A., Mohanam S., Kin Y.et al. A novel function of tissue factor pathway inhibitor-2 (TFPI-2) in human glioma invasion. Oncogene. 20:2001;6938-6945.
4. Rao C.N., Lakka S.S., Kin Y., Konduri S.D., Fuller G.N., Mohanam S.et al. Expression of tissue factor pathway inhibitor 2 inversely correlates during the progression of human gliomas. Clin. Cancer Res. 7:2001;570-576.
5. Herman M.P., Sukhova G.K., Kisiel W., Foster D., Kehry M.R., Libby P.et al. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J. Clin. Invest. 107:2001;1117-1126.
6. van de Locht A., Bode W., Huber R., Le Bonniec B.F., Stone S.R., Esmon C.T.et al. The thrombin E192Q-BPTI complex reveals gross structural rearrangements: implications for the interaction with antithrombin and thrombomodulin. EMBO J. 16:1997;2977-2984.
7. Burgering M.J., Orbons L.P., van der Doelen A., Mulders J., Theunissen H.J., Grootenhuis P.D.et al. The second Kunitz domain of human tissue factor pathway inhibitor: cloning, structure determination and interaction with factor Xa. J. Mol. Biol. 269:1997;395-407.
8. Bajaj M.S., Birktoft J.J., Steer S.A., Bajaj S.P. Structure and biology of tissue factor pathway inhibitor. Thromb. Haemost. 86:2001;959-972.
9. Capasso C., Rizzi M., Menegatti E., Ascenzi P., Bolognesi M. Crystal structure of the bovine alpha-chymotrypsin: Kunitz inhibitor complex. An example of multiple protein:protein recognition sites. J. Mol. Recognit. 10:1997;26-35.
10. Kamei S., Petersen L.C., Sprecher C.A., Foster D.C., Kisiel W. Inhibitory properties of human recombinant Arg24→Gln type-2 tissue factor pathway inhibitor (R24Q TFPI-2). Thromb. Res. 94:1999;147-152.